摘要
α１－受体拮抗剂起初被用来治疗高血压等疾病，最近正越来越多地用于治疗良性前列腺增生。随着α１－受体亚型的不断确证，选择性作用于前列腺的α１－受体拮抗剂研究取得一定进展。不同动物的药理实验结果表明：一些新的化合物比如Ｒｅｃ１５／２７３９（ＳＢ２１６，４６９）、ＳＬ－８９．０５９１以及ＳＮＡＰ５０８９等可能在治疗良性前列腺增生方面比已有药物更具潜力。
? 1 Adrenoceptor antagonists, originally targeted towards hypertension, are being increasingly used in treatment of benign prostatic hyperplasia. The identification of multiple α 1 adrenoceptor subtypes has resulted in progress in the study of compounds which selectively target prostatic α 1 adrenoceptors. Pharmacological experiments in various animal models show that some newer compounds, such as Rec 15/2739, SL 89.0591 and SNAP5089, may provide a potential advantage over the existing agents in treatment of benign prostatic hyperplasia.
出处
《药学进展》
CAS
1999年第2期76-82,共7页
Progress in Pharmaceutical Sciences
